The present invention provides kits, methods and compositions for the
treatment of obesity. The compositions herein contain a substantially
pure preparation of at least one catecholic butane, including, for
example, NDGA compounds in a pharmaceutically acceptable carrier or
excipient. The catecholic butane such as NDGA or its derivatives are
administered to one or more subjects in need of treatment.